What We're Reading: Page 254
Industry reads hand-picked by our editors
Oct 12, 2018
-
Bloomberg
Bayer weighs selling its vet unit in post-Monsanto revamp
-
Fortune
Why cancer biotech Allogene just scored an eye popping $324 million IPO
-
Wired
Antibiotics may soon become useless. Now what?
-
San Francisco Business Times
Tech and biotech on collision course, squeezed by the Peninsula's limited space
-
The Atlantic
Photographing the microscopic: Winners of Nikon Small World 2018
Oct 11, 2018
-
The Wall Street Journal
Biotech is down but far from out
-
Politico
Get ready for a Rx drug-supplement war
-
Xconomy
In New York, Gotham starts up with $54M for RNA-modifying drugs
-
The Washington Post
Republicans and Democrats paint scary visions for health care if the other side wins
Oct 10, 2018
Oct 09, 2018
-
MIT Technology Review
The DNA data storage machine that’s the size of a school bus
-
Bloomberg
Sneaking into patients' pockets, one medical app at a time
-
Crain's Chicago Business
Chicago faces health disparity, biotech leakage, report finds
-
South China Morning Post
Betting big on biotech
Oct 08, 2018
Oct 05, 2018
-
Bloomberg
How a Rundown Square Near Boston Birthed a Biotech Boom and Real Estate Empire
-
MarketWatch
Bio-bonds: A new way to invest in the medical miracles of the future
-
Kaiser Health News
In The Battle To Control Drug Costs, Old Patent Laws Get New Life | Kaiser Health News
-
STAT
A GOP lobbying firm helped launch the latest pro-pharma advocacy group
Oct 04, 2018
-
The Wall Street Journal
Why biotech deal-making has dried up
-
San Francisco Chronicle
Biotech startup that sells 'made to order' DNA plans to go public
-
The Hill
Drug companies fear Democratic Congress
-
Time
How scientists are treating breast cancer using the immune system
Previous
